AHL
FATE icon

Abel Hall LLC’s Fate Therapeutics FATE Stock Holding History

Abel Hall LLC’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.9K Sell
35,872
-876
-2% -$1.62K 0.02% 838
2026
Q1 		$44.1K Buy
+36,748
New +$44.7K 0.01% 754

Other funds holding FATE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
PPW
Parcion Private Wealth Bellevue, Washington $1.8B AUM 30.57% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
NCM
Narwhal Capital Management Marietta, Georgia $1.45B AUM 28.39% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
WP
Westmount Partners Los Angeles, California $457M AUM 31.05% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Abel Hall LLC's FATE Position: Q2 2026 in Review

Abel Hall LLC reduced its Fate Therapeutics (FATE) stake by 2.4% in Q2 2026, selling an estimated $1.62K and leaving 35,872 shares worth $96.9K. The position accounts for 0.02% of the portfolio, ranked #838.

Abel Hall LLC first reported a position in FATE in Q1 2026 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Abel Hall LLC held 35,872 shares of Fate Therapeutics worth $96.9K as of Q2 2026.
  • Abel Hall LLC sold 876 Fate Therapeutics shares in Q2 2026, an estimated $1.62K.
  • Fate Therapeutics made up 0.02% of Abel Hall LLC's portfolio in Q2 2026, its #838 holding.
  • Abel Hall LLC first reported a position in Fate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.